Zydus Lifesciences announced that its U.S. subsidiary Zydus Pharmaceuticals (USA) Inc. has received tentative approval from the United States Food and Drug Administration (USFDA) to market Sugammadex Injection USP 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL), Single-Dose Vial (US RLD: Bridion).
Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. The drug will be manufactured at the group's injectables manufacturing facility at Jarod, India.
Sugammadex Injection had annual sales of USD 772 mn in the United States according to IQVIA MAT July 2022
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
